FDA Approves Six-Month Implant For Opioid Addiction Treatment

On May 26, 2016, the U.S. Food and Drug Administration (FDA) approved Probuphine, a buprenorphine sub-dermal implant for the maintenance treatment of opioid dependence. Probuphine provides a constant, low-level dose of buprenorphine for six months. It is intended for use by consumers who are already stable on low-to-moderate doses of other forms of buprenorphine and who are participating in a complete treatment program that includes counseling and psychosocial support.

Probuphine consists of four, one-inch-long rods that are implanted under the skin on the inside of the upper arm and provide treatment for six . . .